Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JCCG-JN-H-20 high-risk neuroblastoma multimodal chemotherapy and transplantation study
jRCTs041210034Active, not recruiting
- Sponsor
- Japan Agency for Medical Research and Development
- Start
- Jul 2021
- Modality
- RNA-Targeting Small Molecules → Nucleic Acid-Directed Small Molecules → Small Molecules, Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Open-label trial of cyclophosphamide, vincristine, pirarubicin, cisplatin, ifosfamide and 10 more in neuroblastoma (2 arms), sponsored by Japan Agency for Medical Research and Development. Primary endpoint: 3-year progression-free survival rate. Started Jul 2021; status: active, not recruiting.
02
Drugs
cyclophosphamidevincristinepirarubicincisplatinifosfamide
03
Conditions
neuroblastoma
Beyond the preview
Go deeper on jRCTs041210034.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs041210034.